ArticleFuture oncology (London, England)2021
How we treat Merkel cell carcinoma: within and beyond current guidelines.
Article in Future oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and Safety of Treatments for Early-Stage Merkel Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies.Cancer medicine · 2025Pooled it
- Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.American journal of clinical dermatology · 2024Trial
- No Association Between Radiation Dose and Clinical Outcomes in Merkel Cell Carcinoma in the Veteran Population.Advances in radiation oncology · 2026Article
- Merkel-Cell Carcinoma: Local Recurrence Rate Versus Radiation Dose Study from a 949-Patient Database.Current oncology (Toronto, Ont.) · 2025Article
- Merkel cell carcinoma in a patient with basal cell carcinoma: a case of localized disease with negative sentinel node biopsy.Annals of medicine and surgery (2012) · 2025Article
- Sentinel Lymph Node Biopsy: Is There a Role in Non-Melanoma Skin Cancer? A Systematic Review.Cancers · 2024Review
- Article
- Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.International journal of molecular sciences · 2024Review
- Merkel Cell Carcinoma on the Face: Case Report.JMIR dermatology · 2024Article
- Rubella virus chronic inflammatory disease and other unusual viral phenotypes in inborn errors of immunity.Immunological reviews · 2024Review
- Rare but Still There: An Interesting Case of Cytokeratin 20-Negative Merkel Cell Carcinoma.Cureus · 2024Article
- The Evolving Treatment Landscape of Merkel Cell Carcinoma.Current treatment options in oncology · 2023Review
- Article
- Merkel cell carcinoma: a forty-year experience at the Peter MacCallum Cancer Centre.BMC cancer · 2023Article
- Best practices in surgical and nonsurgical management of head and neck Merkel cell carcinoma: An update.Molecular carcinogenesis · 2023Article
- Review
- Defining the Profile of Patients with Primary Merkel Cell Carcinoma in Central Italy: A Retrospective Analysis.Cancers · 2022Article
- Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel.Journal for immunotherapy of cancer · 2022Article
- [Human polyomavirus-associated skin diseases].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2022Review
- Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer.Journal of dermatological science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with a high risk of local recurrence and distant metastasis. Optimal care of this potentially life-threatening cancer is critical but challenging because: physicians are often unfamiliar with its management due to rarity, and MCC management remains controversial, in part because it is rapidly evolving across multiple specialties. While guidelines offer a broad overview of management, they are often not sufficient when making decisions for individual patients. Herein, we present a literature review as well as practical approaches adopted at our institutions for staging, surveillance and therapy of MCC. Each of these areas are discussed in light of how they can be appropriately customized for prevalent but challenging situations. We also provide representative examples of MCC patient scenarios and how they were managed by a multidisciplinary team to identify suitable evidence-based, individualized treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.